Monkasta (Montelukast)

Montelukast, the active ingredient in Monkasta, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in patients requiring controller therapy. GNH USA supplies Monkasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on leukotriene pathways to manage respiratory and allergic conditions.

Asthma: Improves control of chronic airway inflammation and reduces frequency of exacerbations. Allergic rhinitis: Alleviates nasal congestion, sneezing and itching associated with seasonal allergies. Exercise‑induced bronchoconstriction: Prevents narrowing of airways triggered by physical activity.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain in the head. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of sickness or urge to vomit. - Upper respiratory infection: symptoms such as sore throat, cough or congestion.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or severe anaphylaxis. - Mood changes: depression, anxiety, or suicidal thoughts. - Liver enzyme elevation: abnormal liver function test results.

Before initiating therapy, consider the following safety measures.

Pregnancy: safety not established; discuss risks with healthcare provider. Breastfeeding: unknown; weigh benefits against potential risks. Hepatic impairment: use with caution; monitor liver function. Concomitant asthma therapy: may need to continue other controller medications. Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Montelukast can interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Ritonavir: may increase montelukast plasma concentrations. - Phenobarbital: may reduce montelukast effectiveness.

Moderate Interactions (Monitor Closely): - Fluconazole: may modestly increase exposure. - Carbamazepine: may decrease montelukast levels. - Warfarin: monitor INR as montelukast may affect anticoagulation.